This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) | MicrobiomeTrials
← Back to trials NCT07572136
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-07-30Est. Completion: 2030-06-30
Enrollment target: 57 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in B-cell Acute Lymphoblastic Leukemia Diffuse Large B-cell Lymphoma Burkitt Lymphoma Neuroblastoma Ewing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United States Est. completion Mar 31, 2029
Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the po…
Birmingham, United States Est. completion Oct 24, 2030
Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes (MDS) Myeloproliferative Neoplasm
Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and…
Omaha, United States Est. completion Jul 2027